These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35951643)

  • 21. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
    Tutone M; Bjerklund Johansen TE; Cai T; Mushtaq S; Livermore DM
    Int J Antimicrob Agents; 2022 May; 59(5):106574. PubMed ID: 35307561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between bactericidal activity of fosfomycin trometamol in an in vitro model of the urinary bladder and susceptibility testing.
    Pinasi C; Albini E; Marca G
    Eur Urol; 1987; 13 Suppl 1():80-5. PubMed ID: 3569383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experience of using the antibacterial drug Fosfomycin Esparma for the treatment of acute uncomplicated cystitis in women].
    Aboyan IA; Orlov YN; Voloshina OA; Orlov NV; Pavlov DS
    Urologiia; 2019 Sep; (4):20-25. PubMed ID: 31535800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women.
    Minassian MA; Lewis DA; Chattopadhyay D; Bovill B; Duckworth GJ; Williams JD
    Int J Antimicrob Agents; 1998 Apr; 10(1):39-47. PubMed ID: 9624542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
    Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
    Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.
    Burgos RM; Rodvold KA
    Future Microbiol; 2019 Apr; 14():461-475. PubMed ID: 30854892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential of fosfomycin in treating multidrug-resistant infections in children.
    Williams PC
    J Paediatr Child Health; 2020 Jun; 56(6):864-872. PubMed ID: 32294306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The trometamol salt of fosfomycin: microbiological evaluation.
    Greenwood D; Coyle S; Andrew J
    Eur Urol; 1987; 13 Suppl 1():69-75. PubMed ID: 3552702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fosfomycin for UTIs.
    Drug Ther Bull; 2016 Oct; 54(10):114-117. PubMed ID: 27737907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fosfomycin trometamol: activity in vitro against urinary tract pathogens.
    Greenwood D
    Infection; 1990; 18 Suppl 2():S60-4. PubMed ID: 2286463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
    Shorr AF; Pogue JM; Mohr JF
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New ways of using old antibiotics in pediatrics: Focus on fosfomycin.
    Tran MT
    Pharmacotherapy; 2023 Jul; 43(7):705-712. PubMed ID: 36825460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
    Neuner EA; Sekeres J; Hall GS; van Duin D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of fosfomycin in the management of urinary tract infections].
    Zaitsev AV; Kolontarev KB
    Urologiia; 2017 Sep; (4):91-96. PubMed ID: 28952700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.
    Babiker A; Clarke L; Doi Y; Shields RK
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114856. PubMed ID: 31307867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated Expression of GlpT and UhpT via FNR Activation Contributes to Increased Fosfomycin Susceptibility in Escherichia coli under Anaerobic Conditions.
    Kurabayashi K; Tanimoto K; Fueki S; Tomita H; Hirakawa H
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6352-60. PubMed ID: 26248376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.